SlideShare a Scribd company logo
CHRONIC OBSTRUCTIVE LUNG
DISEASE [COPD]
DR. GARGEE KARADKAR
ASSOCIATE PROFESSOR
BVDUCON, NAVI MUMBAI
1
2
COPD – INTRODUCTION
• Chronic obstructive pulmonary disease is a global health
problem that affects millions of people
• Is an important cause of morbidity and mortality
• COPD is one of the top ten causes of death worldwide
• COPD actually represents a spectrum of disease
ranging from destruction of the alveoli and thickening of
the terminal airways on one extreme (emphysema) to
thickening of the airways with chronic inflammation and
repeated bouts of infection (chronic bronchitis) on the
other extreme.
3
COPD – DEFINITION
1. Chronic obstructive pulmonary disease
(COPD) is a disease state characterized by
airflow limitation that is not fully reversible.
2. COPD is characterized by persistent
irreversible respiratory symptoms and airflow
limitation due to airway and/or alveolar
abnormalities, usually caused by significant
exposure to noxious particles or gases”
- Global Initiative for Chronic Obstructive
Lung Disease (GOLD; referred to as the GOLD report)
COPD – ETIOLOGY
1. Smoking
- 85 to 90 percent of all COPD cases caused
by cigarette smoking.
2. Surrounding Environment – Work / Home
- Long-term exposure to air pollution,
secondhand smoke and dust, fumes and
chemicals (which are often work-related)
3. Deficiency of alpha1- antitrypsin-
- Genetic cause (inherited)
- affects the body's ability to produce a protein
(Alpha-1) that protects the lungs.
5
COPD – RISK FACTORS
1. Exposure to tobacco smoke accounts for estimated
80% to 90% of COPD.
2. Passive smoking; breathing second hand smoke.
3. Occupational exposure.
4. Exposure to air pollution.
4. Working with dust or fumes
5. History of childhood respiratory infection
6
COPD - PATHOPHYSIOLOGY
Pathologic changes in the lung consists of:
1. Hyperplasia of mucous secreting glands in the
trachea and bronchi
2. Disappearance of cilia
3. Chronic inflammatory changes and narrowing
of small airways.
4. Altered function of alveolar macrophages
leading to increased bronchial infections.
7
10
COPD INCLUDES CHANGES AS
FOLLOWS
CHRONIC BRONCHITIS EMPHYSEMA
DISEASE OF AIRWAYS IMPAIRED GAS EXCHANGE
COUGH & SPUTUM
PRODUCTION
DESTRUCTION OF WALLS OF
OVERDISTENDED ALVEOLI
3 MONTHS IN 2 YEARS
CONSECUTIVELY END STAGE – PROGRESS OF
DISEASE
11
CHRONIC BRONCHITIS
12
EMPHYSEMA – TYPES
• Destruction of
respiratory bronchiole,
alveolar duct, & alveoli
• Air spaces within the
PANLOBULAR
(PANACINAR)
lobule are enlarged
CENTRILOBUL
AR • Changes in the center
of the secondary
lobule
(CENTRIACINA
R) • Hypoemia &
Hypecapnia
13
EMPHYSEMA
14
CHANGES IN EMPHYSEMA
EARLY STAGE
Walls of the alveoli are destroyed
(a process accelerated by recurrent infections)
the alveolar surface area in direct contact with
the pulmonary capillaries continually decreases
Causes an increase in dead space
(lung area where no gas exchange can occur)
Impaired oxygen diffusion
leads to hypoxemia
15
CHANGES IN EMPHYSEMA
LATER STAGE
Impairment of carbon dioxide elimination
Increases carbon dioxide tension in arterial blood
(hypercapnia) and causing respiratory acidosis
As the alveolar walls continue to break down, the
pulmonary capillary bed is reduced
Causes increase in pulmonary blood flow forcing the
right ventricle to maintain a higher blood pressure in the
pulmonary artery
Hypoxemia may further increase pulmonary artery
pressure
16
17
COPD – CLINICAL MANIFESTATIONS
►Frequent & CHRONIC productive cough
►Sputum production
►Dyspnea on exertion
►Broncho -spasm occur at the end of paroxysm of
coughing
►Weight loss
►Frequent respiratory infections
►Barrel chest [emphysema]
►Contraction of abdominal muscles on inspiration
18
COPD (Chronic obstructive pulmonary disease )
20
21
COPD – DIAGNOSIS
•Patient History
•Ask about onset and duration of current symptoms
•History of smoking or occupational exposure,
allergy, other lung and heart diseases, nasal
polyps, alcohol and tobacco use, unintentional
weight loss, activity restrictions, fatigue
•Sleep patterns
•Current medications. 22
COPD – DIAGNOSIS
• Physical Findings of Particular Interest
• Lung auscultation will identify wheezes, rales, rhonchi,
and decreased breath sounds; sputum might be
purulent in patients with acute exacerbation and
bacterial respiratory tract infection
• Dyspnea and fatigue can be evident during meals, when
walking, and even at rest
• Capacity for independence with ADLs diminished
• Patients with emphysema can be cachec23 tic
COPD – DIAGNOSIS
•LABORATORY TESTS
• ARTERIAL BLOOD GAS
• In Chronic bronchitis : ABGs will show hypercapnia and
hypoxia;
• In emphysema: ABGs usually show normal PaCO2 and can
show mild hypoxia
• COMPLETE BLOOD COUNT
- leukocytosis, elevated Haematocrit - indicating polycythemia
• SPIROMETRY
• Ratio of FEV1 (volume of air that the patient can forcibly exhale
in 1 second) to forced vital capacity (FVC).
• Obstructive lung disease is defined as a FEV1/FVC ratio of24
less
COPD – DIAGNOSIS
•ALPHA-1 ANTITRYPSIN SCREENING
- Can be performed in patients who are < 45 years
of age or patients who have a blood relative with
COPD
•CULTURE – BLOOD & SPUTUM
- If respiratory tract infection is suspected
•B - TYPE NATRIURETIC PEPTIDE (BNP)
- if congestive heart failure is suspected
25
COPD (Chronic obstructive pulmonary disease )
COPD – MEDICAL MANAGEMENT
Treatment goals:
1. Improve ventilation
2. To facilitate the removal of bronchial secretions
3. To prevent complications
4. To slow the progression of clinical manifestations.
5. To promote health maintenance
27
MEDICAL MANAGEMENT
I. PHARMACOTHERAPY
a) Bronchodilators (beta-adrenergic agonists,
anticholinergic agents, and methylxanthines) – Via
MDI/nebulization/per oral – relieve bronchospasm &
reduce airway obstruction
For Stage I or Mild COPD – single bronchodilator
For Stage II or Moderate COPD – 1 / more bronchodilators
+ corticosteroids
b) Inhaled & Systemic Corticosteroids – For stage II or
III COPD patients
c) Antibiotics – in c/o respiratory infection contd
28
MEDICAL MANAGEMENT
II. REMOVE BRONCHIAL SECRETIONS
ØPulmonary hygiene
ØPostural drainage
III. RESPIRATORY THERAPY
ØBreathing retraining
ØEffective coughing techniques
ØChest physiotherapy
ØAerosol nebulization therapy
contd
29
Chest Physiotherapy
30
Postural Drainage
31
MEDICAL MANAGEMENT
IV. OXYGEN THERAPY
►Low flow delivery devices
►High flow delivery devices
►Complications of O2 therapy
►Infection; Oxygen toxicity; CO2 narcosis; Absorption
atelectasis
V. MECHANICAL VENTILATION
In case of severe attack [acute severe exacerbation]
VI. ALPHA 1 ANTITRYPSIN THERAPY
VII. INFLUENZA AND PNEUMOCOCCAL VACCINES 32
MEDICAL MANAGEMENT
VIII. PROMOTE EXERCISE
ØAerobic exercise
ØProgressively increased walking
ØBreathing exercise
33
SURICAL MANAGEMENT
1. BULLECTOMY
Bullae are enlarged airspaces that do not
contribute to ventilation but occupy space in the
thorax; these areas may be surgically excised. It
may help reduce dyspnea and improve lung
function
34
SURICAL MANAGEMENT
2. LUNG VOLUME REDUCTION SURGERY
•For patients with end-stage COPD (stage III)
with a primary emphysema.
•It involves the removal of a portion of the
diseased lung parenchyma.
•This allows the functional tissue to expand,
resulting in improved elastic recoil of the lung
and improved chest wall and diaphragmatic
mechanics.
•It may decrease dyspnea, improve lung
function, and improve the patient’s overall
quality of life 35
36
SURGICAL MANAGEMENT
III. LUNG TRANSPLANTATION
•For patients with end-stage emphysema; improves
quality of life and functional capacity (NIH, 2001).
•Specific criteria exist for referral for lung
transplantation; however, organs are in short
supply and many patients die while waiting for a
transplant
37
COPD (Chronic obstructive pulmonary disease )
IMPROVE GENERAL HEALTH
ØStop smoking
ØMinimize exposure to allergens
ØAvoid high altitudes
ØAdequate nutrition
40
NURSING MANAGEMENT
1. Nursing Assessment:
q Subjective data (health information, functional
health pattern)
q Objective data (Head to foot examination)
41
NURSING MANAGEMENT
1. Impaired gas exchange and airway clearance due to
chronic inhalation of toxins
2. Impaired gas exchange related to ventilation–perfusion
inequality
3. Ineffective airway clearance related to
bronchoconstriction, increased mucus production,
ineffective cough, bronchopulmonary infection, and
other complications
4. Ineffective breathing pattern related to shortness of
breath, mucus, bronchoconstriction, and airway
irritants
5. Activity intolerance due to fatigue, ineffective breathing
patterns, and hypoxemia
6. Deficient knowledge of self-care strategies to be
performed at home.
7. Ineffective coping related to reduced socialization,
anxiety, depression, lower activity level, and the 42
PATIENT EDUCATION AND HOME
CARE
1. Teach adaptive breathing techniques
2. Airway clearance technique
3. Avoid contact with persons who have URTI.
4. Importance of prescribed medications
5. Teach the family how to manage during
acute attacks of dyspnea.
6. Report any change in the health status
7. Avoid dust producing articles at home and
stop smoking.
8. Adequate fluid intake
9. Food choice modification
43
COMPLICATIONS OF COPD
1) Respiratory insufficiency or failure
2) Atelectasis
3) Acute exacerbation of Chronic Bronchitis
4) Pulmonary infection; pneumonia
5) Pneumothorax
6) Pulmonary hypertension
7) Cor pulmonale
44
THANK YOU
45

More Related Content

PDF
Pneumonia (1).pdf
Gargee karadkar
 
PDF
Asthama.pdf
Gargee karadkar
 
PPTX
Bronchitis
Zuzyrie Garrovillas
 
PPTX
Chronic obstructive pulmonary diseases & Nursing care.
V4Veeru25
 
PPTX
Pneumonia
Eko Priyanto
 
PPTX
BRONCHIECTASIS
32KISHOREKUMAR
 
PPTX
Pulmonary TB (Tuberculosis) PPT SlideShare
sonam
 
PPTX
Asthma
Akhil Raj
 
Pneumonia (1).pdf
Gargee karadkar
 
Asthama.pdf
Gargee karadkar
 
Chronic obstructive pulmonary diseases & Nursing care.
V4Veeru25
 
Pneumonia
Eko Priyanto
 
BRONCHIECTASIS
32KISHOREKUMAR
 
Pulmonary TB (Tuberculosis) PPT SlideShare
sonam
 
Asthma
Akhil Raj
 

What's hot (20)

PPT
Pleuresy
aiyub medicine
 
PPTX
COPD(chronic obstructive pulmonary disease) ppt slideshare
sonam
 
PPTX
Bronchitis
DR .PALLAVI PATHANIA
 
PPTX
Bronchial Asthma: Definition,Pathophysiology and Management
Marko Makram
 
PPTX
Bronchiectasis
Pratap Tiwari
 
PPT
Lecture 5 asthma and copd
Mohanad Mohanad
 
PPTX
Copd
Sandra McClain
 
PPTX
Chronic obstructive pulmonary disease (copd) power point
wandatardy
 
PPTX
Emphysema ppt
VemuJhansi
 
PPTX
pneumonia
Hasnah Noi
 
PPTX
Atelectasis
Mr. Mata Deen
 
PPTX
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Dr.Deepika T
 
PDF
ATELECTEASIS
Gargee karadkar
 
PPTX
bronchitis (pathology and treatment)by srota dawn
Srota Dawn
 
PPTX
Emphysema
Layla Aziz
 
PPTX
Bronchiectasis
HaiderAlkhafaji5
 
PPTX
Chronic obstructive lung disease(copd)
CutiePie35
 
PPTX
Pneumonia
Firoz Hakkim
 
Pleuresy
aiyub medicine
 
COPD(chronic obstructive pulmonary disease) ppt slideshare
sonam
 
Bronchial Asthma: Definition,Pathophysiology and Management
Marko Makram
 
Bronchiectasis
Pratap Tiwari
 
Lecture 5 asthma and copd
Mohanad Mohanad
 
Chronic obstructive pulmonary disease (copd) power point
wandatardy
 
Emphysema ppt
VemuJhansi
 
pneumonia
Hasnah Noi
 
Atelectasis
Mr. Mata Deen
 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Dr.Deepika T
 
ATELECTEASIS
Gargee karadkar
 
bronchitis (pathology and treatment)by srota dawn
Srota Dawn
 
Emphysema
Layla Aziz
 
Bronchiectasis
HaiderAlkhafaji5
 
Chronic obstructive lung disease(copd)
CutiePie35
 
Pneumonia
Firoz Hakkim
 
Ad

Similar to COPD (Chronic obstructive pulmonary disease ) (20)

PPTX
Chronic Obstructive Pulmonary Disease (COPD).pptx
Ibrahim Ahmed Nur
 
PPTX
Chronic obstructive pulmunary disease DR. Parshant
Ps Nadda
 
PPTX
CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY AKRAM KHAN
Akram Khan
 
PPTX
COPD.pptx
AnubhavKumar871
 
PPTX
COPD.pptx
yilkalmossie1
 
PPTX
Chronic Obstructive Pulmonary Disease[ COPD].pptx
akoeljames8543
 
PPTX
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
ShylaMercy
 
PPTX
Copd Part 1
Pratap Tiwari
 
PPTX
Copd ppt
shubham sharma
 
PPT
chronic obstructive pulmoary disease
Raghunandan Singh
 
PPTX
COPD.pptx
sapnabohra2
 
PPTX
Chronic Obstructive Pulmonary Disease
Dr. Koppala R.V.S. Chaitanya
 
PPTX
COPD.pptx
RAHULSUTHAR46
 
PPTX
COPD ppt
narendra meena
 
PDF
COPD and AE of COPD
Asraf Hussain
 
PPTX
CHRONIC OBSTRUCTIVE PULMONARY DISEASE and ATHSMA.pptx
nanaquameatoampomah
 
Chronic Obstructive Pulmonary Disease (COPD).pptx
Ibrahim Ahmed Nur
 
Chronic obstructive pulmunary disease DR. Parshant
Ps Nadda
 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY AKRAM KHAN
Akram Khan
 
COPD.pptx
AnubhavKumar871
 
COPD.pptx
yilkalmossie1
 
Chronic Obstructive Pulmonary Disease[ COPD].pptx
akoeljames8543
 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
ShylaMercy
 
Copd Part 1
Pratap Tiwari
 
Copd ppt
shubham sharma
 
chronic obstructive pulmoary disease
Raghunandan Singh
 
COPD.pptx
sapnabohra2
 
Chronic Obstructive Pulmonary Disease
Dr. Koppala R.V.S. Chaitanya
 
COPD.pptx
RAHULSUTHAR46
 
COPD ppt
narendra meena
 
COPD and AE of COPD
Asraf Hussain
 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE and ATHSMA.pptx
nanaquameatoampomah
 
Ad

Recently uploaded (20)

PPTX
1.2) Congestive Cardiac Failure.pptx Cardiovascular disease
Dr. Sarita Sharma
 
PPTX
4. Basic Principles managment of dislocation.pptx
orthojju
 
PDF
Opening discussion for urban disease control and its challenges
Phathai Singkham
 
DOCX
RUHS II MBBS Pathology Paper-II with Answer Key | 1st August 2025 (New Scheme)
Shivankan Kakkar
 
PDF
Chronic pelvic pain gynecology slides.pdf
alifaisal9338
 
PPTX
CVS INTRO.pptx therapeutics Cardiovascular disease
Dr. Sarita Sharma
 
PDF
coagulation disorders in anaesthesia pdf
Assist. Prof. Radhwan Hazem Alkhashab
 
PPTX
Acute abdomen in Gyne Obs obstetrics.pptxandGynaecology.pptx
abdiwmh75
 
PPTX
CLABSI-CAUTI (CENTRAL LINE ASSOCIATED BLOOD STREAM INFECTIONS & CATHETER ASSO...
Dr.Vaidyanathan R
 
PPTX
Optimal sites for mini-implant insertion into the infrazygomatic crest accord...
Dr Anurag JB
 
PPTX
NEET PG 2025: Memory-Based Recall Questions Compiled by Dr. Shivankan Kakkar, MD
Shivankan Kakkar
 
PDF
Writing and Teaching as Personal Documentation of Continuing Professional Dev...
Robertus Arian Datusanantyo
 
PDF
Consanguineous Marriages: A Multidisciplinary Analysis of Sociocultural, Gene...
GAURAV. H .TANDON
 
PPTX
Anaesthesia Machine - Safety Features and Recent Advances - Dr.Vaidyanathan R
VAIDYANATHAN R
 
PPTX
CANSA Womens Health UTERINE focus Top Cancers slidedeck Aug 2025
CANSA The Cancer Association of South Africa
 
PPTX
LOW GRADE GLIOMA MANAGEMENT BY DR KANHU CHARAN PATRO
Kanhu Charan
 
PDF
NEET PG-2023 Expected questions and topics
Abhishek107368
 
PDF
Bassem Matta, CCMA
Smiling Lungs
 
PPTX
ABO Blood grouping serological practices against the standard and challenges ...
AbrarKabir3
 
DOCX
NEET PG 2025 | Pharmacology Recall: 20 High-Yield Questions Simplified
Shivankan Kakkar
 
1.2) Congestive Cardiac Failure.pptx Cardiovascular disease
Dr. Sarita Sharma
 
4. Basic Principles managment of dislocation.pptx
orthojju
 
Opening discussion for urban disease control and its challenges
Phathai Singkham
 
RUHS II MBBS Pathology Paper-II with Answer Key | 1st August 2025 (New Scheme)
Shivankan Kakkar
 
Chronic pelvic pain gynecology slides.pdf
alifaisal9338
 
CVS INTRO.pptx therapeutics Cardiovascular disease
Dr. Sarita Sharma
 
coagulation disorders in anaesthesia pdf
Assist. Prof. Radhwan Hazem Alkhashab
 
Acute abdomen in Gyne Obs obstetrics.pptxandGynaecology.pptx
abdiwmh75
 
CLABSI-CAUTI (CENTRAL LINE ASSOCIATED BLOOD STREAM INFECTIONS & CATHETER ASSO...
Dr.Vaidyanathan R
 
Optimal sites for mini-implant insertion into the infrazygomatic crest accord...
Dr Anurag JB
 
NEET PG 2025: Memory-Based Recall Questions Compiled by Dr. Shivankan Kakkar, MD
Shivankan Kakkar
 
Writing and Teaching as Personal Documentation of Continuing Professional Dev...
Robertus Arian Datusanantyo
 
Consanguineous Marriages: A Multidisciplinary Analysis of Sociocultural, Gene...
GAURAV. H .TANDON
 
Anaesthesia Machine - Safety Features and Recent Advances - Dr.Vaidyanathan R
VAIDYANATHAN R
 
CANSA Womens Health UTERINE focus Top Cancers slidedeck Aug 2025
CANSA The Cancer Association of South Africa
 
LOW GRADE GLIOMA MANAGEMENT BY DR KANHU CHARAN PATRO
Kanhu Charan
 
NEET PG-2023 Expected questions and topics
Abhishek107368
 
Bassem Matta, CCMA
Smiling Lungs
 
ABO Blood grouping serological practices against the standard and challenges ...
AbrarKabir3
 
NEET PG 2025 | Pharmacology Recall: 20 High-Yield Questions Simplified
Shivankan Kakkar
 

COPD (Chronic obstructive pulmonary disease )

  • 1. CHRONIC OBSTRUCTIVE LUNG DISEASE [COPD] DR. GARGEE KARADKAR ASSOCIATE PROFESSOR BVDUCON, NAVI MUMBAI 1
  • 2. 2
  • 3. COPD – INTRODUCTION • Chronic obstructive pulmonary disease is a global health problem that affects millions of people • Is an important cause of morbidity and mortality • COPD is one of the top ten causes of death worldwide • COPD actually represents a spectrum of disease ranging from destruction of the alveoli and thickening of the terminal airways on one extreme (emphysema) to thickening of the airways with chronic inflammation and repeated bouts of infection (chronic bronchitis) on the other extreme. 3
  • 4. COPD – DEFINITION 1. Chronic obstructive pulmonary disease (COPD) is a disease state characterized by airflow limitation that is not fully reversible. 2. COPD is characterized by persistent irreversible respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities, usually caused by significant exposure to noxious particles or gases” - Global Initiative for Chronic Obstructive Lung Disease (GOLD; referred to as the GOLD report)
  • 5. COPD – ETIOLOGY 1. Smoking - 85 to 90 percent of all COPD cases caused by cigarette smoking. 2. Surrounding Environment – Work / Home - Long-term exposure to air pollution, secondhand smoke and dust, fumes and chemicals (which are often work-related) 3. Deficiency of alpha1- antitrypsin- - Genetic cause (inherited) - affects the body's ability to produce a protein (Alpha-1) that protects the lungs. 5
  • 6. COPD – RISK FACTORS 1. Exposure to tobacco smoke accounts for estimated 80% to 90% of COPD. 2. Passive smoking; breathing second hand smoke. 3. Occupational exposure. 4. Exposure to air pollution. 4. Working with dust or fumes 5. History of childhood respiratory infection 6
  • 7. COPD - PATHOPHYSIOLOGY Pathologic changes in the lung consists of: 1. Hyperplasia of mucous secreting glands in the trachea and bronchi 2. Disappearance of cilia 3. Chronic inflammatory changes and narrowing of small airways. 4. Altered function of alveolar macrophages leading to increased bronchial infections. 7
  • 8. 10
  • 9. COPD INCLUDES CHANGES AS FOLLOWS CHRONIC BRONCHITIS EMPHYSEMA DISEASE OF AIRWAYS IMPAIRED GAS EXCHANGE COUGH & SPUTUM PRODUCTION DESTRUCTION OF WALLS OF OVERDISTENDED ALVEOLI 3 MONTHS IN 2 YEARS CONSECUTIVELY END STAGE – PROGRESS OF DISEASE 11
  • 11. EMPHYSEMA – TYPES • Destruction of respiratory bronchiole, alveolar duct, & alveoli • Air spaces within the PANLOBULAR (PANACINAR) lobule are enlarged CENTRILOBUL AR • Changes in the center of the secondary lobule (CENTRIACINA R) • Hypoemia & Hypecapnia 13
  • 13. CHANGES IN EMPHYSEMA EARLY STAGE Walls of the alveoli are destroyed (a process accelerated by recurrent infections) the alveolar surface area in direct contact with the pulmonary capillaries continually decreases Causes an increase in dead space (lung area where no gas exchange can occur) Impaired oxygen diffusion leads to hypoxemia 15
  • 14. CHANGES IN EMPHYSEMA LATER STAGE Impairment of carbon dioxide elimination Increases carbon dioxide tension in arterial blood (hypercapnia) and causing respiratory acidosis As the alveolar walls continue to break down, the pulmonary capillary bed is reduced Causes increase in pulmonary blood flow forcing the right ventricle to maintain a higher blood pressure in the pulmonary artery Hypoxemia may further increase pulmonary artery pressure 16
  • 15. 17
  • 16. COPD – CLINICAL MANIFESTATIONS ►Frequent & CHRONIC productive cough ►Sputum production ►Dyspnea on exertion ►Broncho -spasm occur at the end of paroxysm of coughing ►Weight loss ►Frequent respiratory infections ►Barrel chest [emphysema] ►Contraction of abdominal muscles on inspiration 18
  • 18. 20
  • 19. 21
  • 20. COPD – DIAGNOSIS •Patient History •Ask about onset and duration of current symptoms •History of smoking or occupational exposure, allergy, other lung and heart diseases, nasal polyps, alcohol and tobacco use, unintentional weight loss, activity restrictions, fatigue •Sleep patterns •Current medications. 22
  • 21. COPD – DIAGNOSIS • Physical Findings of Particular Interest • Lung auscultation will identify wheezes, rales, rhonchi, and decreased breath sounds; sputum might be purulent in patients with acute exacerbation and bacterial respiratory tract infection • Dyspnea and fatigue can be evident during meals, when walking, and even at rest • Capacity for independence with ADLs diminished • Patients with emphysema can be cachec23 tic
  • 22. COPD – DIAGNOSIS •LABORATORY TESTS • ARTERIAL BLOOD GAS • In Chronic bronchitis : ABGs will show hypercapnia and hypoxia; • In emphysema: ABGs usually show normal PaCO2 and can show mild hypoxia • COMPLETE BLOOD COUNT - leukocytosis, elevated Haematocrit - indicating polycythemia • SPIROMETRY • Ratio of FEV1 (volume of air that the patient can forcibly exhale in 1 second) to forced vital capacity (FVC). • Obstructive lung disease is defined as a FEV1/FVC ratio of24 less
  • 23. COPD – DIAGNOSIS •ALPHA-1 ANTITRYPSIN SCREENING - Can be performed in patients who are < 45 years of age or patients who have a blood relative with COPD •CULTURE – BLOOD & SPUTUM - If respiratory tract infection is suspected •B - TYPE NATRIURETIC PEPTIDE (BNP) - if congestive heart failure is suspected 25
  • 25. COPD – MEDICAL MANAGEMENT Treatment goals: 1. Improve ventilation 2. To facilitate the removal of bronchial secretions 3. To prevent complications 4. To slow the progression of clinical manifestations. 5. To promote health maintenance 27
  • 26. MEDICAL MANAGEMENT I. PHARMACOTHERAPY a) Bronchodilators (beta-adrenergic agonists, anticholinergic agents, and methylxanthines) – Via MDI/nebulization/per oral – relieve bronchospasm & reduce airway obstruction For Stage I or Mild COPD – single bronchodilator For Stage II or Moderate COPD – 1 / more bronchodilators + corticosteroids b) Inhaled & Systemic Corticosteroids – For stage II or III COPD patients c) Antibiotics – in c/o respiratory infection contd 28
  • 27. MEDICAL MANAGEMENT II. REMOVE BRONCHIAL SECRETIONS ØPulmonary hygiene ØPostural drainage III. RESPIRATORY THERAPY ØBreathing retraining ØEffective coughing techniques ØChest physiotherapy ØAerosol nebulization therapy contd 29
  • 30. MEDICAL MANAGEMENT IV. OXYGEN THERAPY ►Low flow delivery devices ►High flow delivery devices ►Complications of O2 therapy ►Infection; Oxygen toxicity; CO2 narcosis; Absorption atelectasis V. MECHANICAL VENTILATION In case of severe attack [acute severe exacerbation] VI. ALPHA 1 ANTITRYPSIN THERAPY VII. INFLUENZA AND PNEUMOCOCCAL VACCINES 32
  • 31. MEDICAL MANAGEMENT VIII. PROMOTE EXERCISE ØAerobic exercise ØProgressively increased walking ØBreathing exercise 33
  • 32. SURICAL MANAGEMENT 1. BULLECTOMY Bullae are enlarged airspaces that do not contribute to ventilation but occupy space in the thorax; these areas may be surgically excised. It may help reduce dyspnea and improve lung function 34
  • 33. SURICAL MANAGEMENT 2. LUNG VOLUME REDUCTION SURGERY •For patients with end-stage COPD (stage III) with a primary emphysema. •It involves the removal of a portion of the diseased lung parenchyma. •This allows the functional tissue to expand, resulting in improved elastic recoil of the lung and improved chest wall and diaphragmatic mechanics. •It may decrease dyspnea, improve lung function, and improve the patient’s overall quality of life 35
  • 34. 36
  • 35. SURGICAL MANAGEMENT III. LUNG TRANSPLANTATION •For patients with end-stage emphysema; improves quality of life and functional capacity (NIH, 2001). •Specific criteria exist for referral for lung transplantation; however, organs are in short supply and many patients die while waiting for a transplant 37
  • 37. IMPROVE GENERAL HEALTH ØStop smoking ØMinimize exposure to allergens ØAvoid high altitudes ØAdequate nutrition 40
  • 38. NURSING MANAGEMENT 1. Nursing Assessment: q Subjective data (health information, functional health pattern) q Objective data (Head to foot examination) 41
  • 39. NURSING MANAGEMENT 1. Impaired gas exchange and airway clearance due to chronic inhalation of toxins 2. Impaired gas exchange related to ventilation–perfusion inequality 3. Ineffective airway clearance related to bronchoconstriction, increased mucus production, ineffective cough, bronchopulmonary infection, and other complications 4. Ineffective breathing pattern related to shortness of breath, mucus, bronchoconstriction, and airway irritants 5. Activity intolerance due to fatigue, ineffective breathing patterns, and hypoxemia 6. Deficient knowledge of self-care strategies to be performed at home. 7. Ineffective coping related to reduced socialization, anxiety, depression, lower activity level, and the 42
  • 40. PATIENT EDUCATION AND HOME CARE 1. Teach adaptive breathing techniques 2. Airway clearance technique 3. Avoid contact with persons who have URTI. 4. Importance of prescribed medications 5. Teach the family how to manage during acute attacks of dyspnea. 6. Report any change in the health status 7. Avoid dust producing articles at home and stop smoking. 8. Adequate fluid intake 9. Food choice modification 43
  • 41. COMPLICATIONS OF COPD 1) Respiratory insufficiency or failure 2) Atelectasis 3) Acute exacerbation of Chronic Bronchitis 4) Pulmonary infection; pneumonia 5) Pneumothorax 6) Pulmonary hypertension 7) Cor pulmonale 44